Posts

Gossamer Bio Stock Nosedives After Late-Stage Seralutinib Failure in PAH Trial

on

Merck Makes Strong Case for Winrevair in Earlier-Stage Pulmonary Arterial Hypertension (PAH) Patients After Positive Phase 3 HYPERION Results

on

Insmed's 'Unprecedented' Phase 2 PAH Results Propel Stock and Next-Phase Plans

on

Insmed's TPIP PAH Therapy Advances to Phase III Following Positive Phase 2b Results

on

Keros Therapeutics Halts Pulmonary Hypertension Drug After Safety Issues, Cuts 45% of Workforce

on

Keros Therapeutics Halts Pulmonary Hypertension Drug After Safety Issues, Cuts 45% of Workforce

on

Merck's Winrevair Slashes Morbidity and Mortality Risk in Pulmonary Arterial Hypertension

on